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INTRODUCTION
Leptin, the adipocyte derived hormone, has potent effects on lipid metabolism.
Of these, leptin-induced stimulation of fatty acid oxidation and decreases in circulating and tissue levels of triglyceride are best described (11, 25, 26, 36, 37, 43, 49, 55) . In addition to a role in the regulation of lipid metabolism, the beneficial effects of leptin on insulin sensitivity are well established. Thus, insulin resistance in leptin deficient states resulting from leptin gene mutations or lipodystrophy is markedly improved by leptin administration in humans (29, 52) and rodents (5, 21, 38, 50) . A primary site of leptin action appears to be skeletal muscle, since leptin increases insulin-stimulated glucose uptake into this tissue (3, 11, 43, 54, 60, 61) . Leptin-induced increases in insulin sensitivity are also associated with substantial improvements in the dyslipidemia associated with leptin deficient/resistant states (5, 11, 16, 29, 38, 43, 49, 52) . Arising from these observations, it has been proposed that the beneficial effects of leptin on lipid metabolism may contribute to improvements in insulin sensitivity, a hypothesis supported by studies demonstrating detrimental effects of lipids on insulin action (2, 7, 12, 20, 22, 27, 31, 39, 41, 58, 62) .
In humans and rodents there is a strong negative correlation between plasma and tissue triglyceride levels and insulin sensitivity (22, 31, 34, 51) . Furthermore, acute infusions of lipid induce skeletal muscle insulin resistance in vivo (2, 6, 7, 12, 15, 20, 27, 62 ) and fatty acids induce insulin resistance in skeletal muscle cell lines in vitro (13, 48, 53) . In addition to triglycerides, a number of other lipid metabolites have been proposed to contribute to the detrimental effects of lipids on insulin sensitivity in muscle. In short, there is evidence (1, 13, 47, 48, 57, 59, 62 ) that increased levels of diacylglycerol (DAG) Page 3 of 37 and/or ceramide contribute to decreased insulin action, effects that possibly involve activation of the novel protein kinase C-(PKC ) and/or inhibition of Akt (4, 13, 20, 27, 30, 47, 48, 57, 62) . However, the effects of leptin on muscle ceramide and DAG levels and insulin signaling pathways are unknown. Furthermore, the effects of leptin on lipidinduced insulin resistance have not been addressed directly, since previous studies have simply demonstrated a correlation between the effects of leptin on insulin action and lipid metabolism, and were performed in models of pre-existing insulin resistance and hyperlipidemia (ob/ob mouse, diet-induced obesity, and lipodystrophy). Thus, the primary goals of the current study were to address these issues. The data demonstrate that leptin-induced improvements in insulin sensitivity are associated with lowered skeletal muscle TG levels, increased skeletal muscle insulin signaling, decreased levels of PKC , but not with decreases in skeletal muscle levels of DAG and ceramide Furthermore, leptin protects against insulin resistance induced by an acute lipid infusion. Study Design. All studies were performed ~10 days after the insertion of indwelling catheters and five days after adenovirus administration in 18-24 h fasted animals, as described in detail below. Studies measuring insulin sensitivity and skeletal muscle lipid levels were performed in separate groups of animals. To allow comparisons between studies and conditions, assessments of insulin sensitivity and lipid levels were always performed subsequent to a saline or lipid infusion, as described below, except in studies assessing skeletal muscle insulin signaling.
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MATERIALS AND METHODS
Animal
In three studies, the effects of hyperleptinemia, or hyperlipidemia combined with hyperleptinemia, on insulin sensitivity and lipid levels (triglycerides, diacylglycerol, ceramide) in two skeletal muscles differing in fiber-type composition (soleus muscle, a slow twitch, oxidative muscle composed predominantly of type 1 muscle fibers and superficial vastus, a fast twitch, glycolytic muscle composed predominantly of type 2 muscle fibers) were evaluated. The effects of hyperleptinemia on skeletal muscle insulin signaling were assessed in separate studies, as described below.
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Animal Surgeries. Catheters (PE-50, Intramedic, Becton Dickinson, Sparks, MD) were placed into the carotid artery (advanced to the aortic arch) and jugular vein (advanced to the right atrium) 5-10 days prior to a study as described previously (14) . All subsequent studies were performed in animals that achieved at least 90% of presurgery weight.
Recombinant Adenovirus Administration.
In studies requiring hyperleptinemia, chronically catheterized rats (~5 days after surgery) received a recombinant adenovirus containing the leptin cDNA (HL, 1 x 10 12 particles) by tail vein injection as previously described (11) . Control animals received a recombinant adenovirus containing the Escherichia coli -galactosidase cDNA (CONT, 1 x 10 12 particles). Subsequently, CONT were calorically matched to HL to adjust for leptin-induced decreases in food intake, as previously described (11) . Studies (lipid/saline infusions, insulin clamps) described below were performed 5 days after adenovirus administration. Subsequently, 32 P labeled DAGs and ceramides were separated by thin layer chromatography. After completion of the chromatography, the silica plates were exposed to autoradiograph film. Using the developed film for orientation, DAGs and ceramides were located on the silica plate and scraped into separate scintillation vials. Scintillation cocktail was added and the product counted for 1 min. DAG and ceramide concentrations were calculated as nMol per mg protein based on DAG and ceramide standards run in conjunction with test samples. This analysis method gives quantitatively similar data to that obtained using high-performance liquid chromatography-fluorescence spectrometry for total ceramide content, and presumably total DAG content (10).
Furthermore, the concentration of ceramide and DAG reported in this study are similar to those reported using liquid chromatography tandem mass-spectrometry (62) and gasliquid chromatography (19) . ( To determine the equilibration coefficient, 200 µL medium containing a known quantity of tritiated water (10 µCi) was incubated similarly to other samples. After the 18 h incubation, 10 mL of scintillation fluid was added to the vials and the samples counted.
(iv) PI3-kinase activity. IRS-1 associated PI3-kinase activity was measured as previously (FABPpm) and membrane and cytosolic PKC levels were determined using standard immunoblot protocols and as described previously (8, 9, 25) Statistical analysis. All data are expressed as mean ± S.E. Statistical significance was determined by unpaired t-test using the SPSS (Chicago, IL) statistical software.
Significance was assumed at P < 0.05.
RESULTS
Leptin-induced improvements in insulin sensitivity are associated with lowered skeletal muscle triglycerides, increased ceramides and unaltered diacylglycerol levels.
Previously, we demonstrated in obese rats (11) . Surprisingly, ceramide levels were increased, while DAG levels were unaltered by hyperleptinemia in both muscles (Figure 2 , Panels A and B).
Leptin protects against insulin resistance and alterations in skeletal muscle
triglyceride, ceramide, and diacylglycerol levels induced by acute hyperlipidemia. The detrimental effects of acute hyperlipidemia on skeletal muscle insulin sensitivity are well described (7, 12, 24, 33) . As such, this model is ideal for directly assessing the capacity of leptin to protect against the effects of lipids on insulin action. As expected, the glucose infusion rates required to maintain euglycemia was decreased in animals receiving a 6 h lipid infusion (LIP) compared to saline-infused (CONT) animals ( Figure   3 ). These changes in insulin sensitivity were associated with increases in soleus muscle It has been proposed that increased activity/expression of PKC , possibly mediated by DAG, is a contributing mechanism to the development of lipid-induced skeletal muscle insulin resistance (4, 20, 62). Thus, we thought it possible that leptin may decrease PKC activity. Subsequent to lipid infusions, both cytosolic and membrane PKC levels in skeletal muscle were reduced by ~30% (both P<0.05) in HL compared to CONT (Figure 9 ), suggesting one potential biochemical mechanism for the protective effects of leptin against lipid-induced insulin resistance.
DISCUSSION
The purpose of the current study was to gain a greater understanding of the effects of leptin on levels of skeletal muscle lipids implicated in the pathogenesis of insulin resistance, to assess the capacity of leptin to protect against the detrimental effects of lipids on insulin action, and to begin to understand the biochemical basis of leptin action on insulin sensitivity. The data demonstrate that leptin-induced improvements in insulin sensitivity are not clearly associated with decreased levels of skeletal muscle lipids implicated in the pathogenesis of insulin resistance, while insulin resistance induced by acute hyperlipidemia is prevented by leptin. Potential biochemical mechanisms mediating these effects include leptin-induced increases in the responsiveness of the skeletal muscle insulin signaling pathway to insulin and reductions in the levels of skeletal muscle PKC , a kinase implicated in reducing insulin sensitivity.
The association between leptin effects on lipid metabolism and leptin effects on insulin action suggest that the latter effects may be mediated by decreasing the levels of lipid metabolites such as triglyceride, ceramide and DAG that have been implicated in the pathogenesis of lipid-induced insulin resistance (1, 13, 47, 48, 57, 59, 62) . Indeed, leptin has potent lowering effects on plasma and tissue triglyceride levels, but it is thought that triglycerides per se are unlikely to play a direct mechanistic role in altering insulin action.
Rather, the triglyceride lowering effects of leptin are thought to be a surrogate marker for alterations in other lipid metabolic pathways that may alter insulin action. Thus, it was somewhat surprising in the current study that while leptin increased insulin sensitivity, and the increases were associated with decreases in triglyceride levels in both slowtwitch, oxidative (soleus) and fast-twitch, glycolytic (superficial vastus) muscle fibers, there were no corresponding decreases in the levels of either ceramide or DAG. Indeed, ceramide increased in both muscle fiber-types examined in hyperleptinemic animals, while DAG was unchanged. Thus, under the conditions examined here (hyperleptinemia in lean animals) the beneficial effects of leptin on insulin sensitivity occur independently of alterations in the levels of these lipid metabolites.
Previous studies in ob/ob and lipodystrophic mice and diet-induced obese rats Also, in exercise training (18, 46) there is an increase in insulin sensitivity that correlates with increased skeletal muscle oxidative capacity but not with triglyceride levels, which are paradoxically increased. In the current study we did not observe leptin-induced increases in fatty acid oxidation or ACC phosphorylation, although previous studies suggest that there is a stimulatory effect of leptin on fatty acid oxidation in skeletal muscle (35, 49) , possibly mediated by an inactivation of ACC and relief of inhibition of CPT-1. However, it is possible that the model we used i.e. the isolated muscle, explains the current data since previous studies were performed in vivo (35, 49) or in isolated muscles receiving electrical stimulation (55). Indeed, in this latter study (55) the authors report that fatty acid oxidation was not increased by leptin in non-stimulated muscles, the conditions that were used in the current study. One conclusion that can be made is that leptin-induced genomic changes that would result in enhanced fatty acid oxidation are not occurring, and that sympathetic innervation may be required to observe leptin-induced increases in fatty acid oxidation.
We demonstrate that the capacity of insulin to activate elements of the insulinsignaling pathway in skeletal muscle is improved by leptin, suggesting one biochemical mechanism underlying the beneficial effects of leptin on insulin action. It is also clear that the increases in the responsiveness of the insulin signaling pathway are most closely associated with decreases in skeletal muscle TG, but are not related to decreases in ceramide or DAG. However it is unknown how decreases in TG would improve insulin signaling. Indeed, it remains a possibility that this association is purely correlative, and that the TG level may reflect increases in the activity of other unknown lipid metabolic pathways or fatty acid oxidation, as discussed above. Alternatively, it is important to consider that other mechanisms that may be unrelated to leptin effects on lipid metabolism may mediate leptin effects on insulin signaling. An interesting observation was that insulin-stimulated IRS-1 associated PI3-kinase activity was not increased in HL animals, despite increases in Akt and GSK3 phosphorylation. This was somewhat surprising given that Akt is a proximal downstream target of PI3-kinase activity.
Furthermore, a recent study suggests that leptin inhibits insulin signaling at the level of IRS-1 (23), demonstrating that there is a potentially complex relationship between leptininduced increases in insulin sensitivity and leptin effects on insulin signaling.
Several studies have demonstrated a relationship between increased activation of PKC and insulin resistance. Thus, in response to a lipid infusion in rodents membraneassociated PKC , considered to be the active form of this kinase, is increased, and there is a corresponding decrease in the levels of cytosolic PKC (62). Similarly, in obesity levels of skeletal muscle PKC are increased (28). Furthermore, PKC deficient mice (32) are protected against the effects of acute hyperlipidemia on insulin action. In the current study we demonstrate that both cytosolic and membrane-associated PKC are decreased in hyperleptinemic compared to control animals. Thus, a potential mechanism of beneficial effects of leptin on insulin action is to decrease PKC . The mechanism by which leptin mediates a reduction in PKC is unknown but may be related to effects of leptin on lipid metabolism.
In conclusion, the present study demonstrates that leptin-induced improvements in insulin sensitivity cannot be clearly associated with alterations in skeletal muscle lipid levels. There is an association between leptin effects on insulin action and leptin effects on skeletal muscle triglyceride levels, but this association does not extend to the levels of DAG and ceramide. Under conditions of acute hyperlipidemia, leptin protects against the deleterious effects of lipids on insulin action. Leptin increases the responsiveness of skeletal muscle to insulin as assessed by activation of Akt and inhibition of GSK3 and decreases the levels of PKC , which has been implicated in the pathogenesis of lipidinduced insulin resistance. C.
